Extract

To evaluate the safety and tolerability of atacicept and to explore if atacicept reduces central nervous system inflammation in subjects with relapsing multiple sclerosis (RMS) as assessed by frequent magnetic resonance imaging (MRI). This study is randomised. Study medication is administered via subcutaneous (under the skin) injections.

Inclusion criteria

• Relapsing Multiple Sclerosis

Country

• Australia
• Austria
• Belgium
• Canada
• Czech Republic
• France
• Germany
• Lebanon
• Lithuania
• Netherlands
• Russian Federation
• Spain
• Sweden
• Switzerland
• Ukraine
• United Kingdom
• United States

Links

• ictrp
• nct